deltatrials
Unknown PHASE2 NCT04698941

Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

Clinical Study of Albumin Paclitaxel With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy

Sponsor: Chinese Academy of Sciences

Conditions Small Cell Lung Cancer
Interventions Albumin Paclitaxel Simvastatin
Updated 5 times since 2021 Last updated: Jul 26, 2021 Started: Jul 25, 2021 Primary completion: Dec 30, 2021 Completion: Dec 30, 2022

Listed as NCT04698941, this PHASE2 trial focuses on Small Cell Lung Cancer and remains ongoing. Sponsored by Chinese Academy of Sciences, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Aug 2023 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  4. Sep 2021 — Aug 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Feb 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chinese Academy of Sciences
  • Shanghai Pulmonary Hospital, Shanghai, China
Data source: Shanghai Pulmonary Hospital, Shanghai, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Shanghai, China